Effect of letrozole combined with metformin on endometriosis

Hong Ju, Yi Zhang, Rui Chen
In: Central Plains Medical Journal · 2016 · vol. 43(21) , pp. 89–91 · doi:10.3760/cma.j.issn.1674-4756.2016.21.034 · W3032659989
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-04 ⓘ

A randomized trial of 112 endometriosis patients found that letrozole combined with metformin significantly reduced pain and CA125 levels more effectively than leuprorelin alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-17 · read from full text ⓘ

This randomized controlled trial evaluated the clinical efficacy of combining letrozole with metformin for treating endometriosis compared to leuprorelin monotherapy. The study included 112 patients, finding that the combination therapy significantly improved overall treatment outcomes and reduced recurrence rates more effectively than the control group. Additionally, patients receiving the dual treatment exhibited greater reductions in pain scores and serum CA125 levels post-treatment. This paper is centrally about endometriosis — specifically comparing a hormonal aromatase inhibitor combined with an insulin sensitizer against a standard GnRH agonist regimen.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objective To observe the clinical effect of letrozole combined with metformin on endometriosis. Methods One hundred and twelve cases of endometriosis from October 2013 to November 2014 were randomly divided into control group and treatment group, with 56 cases in each group. The control group was given leuprorelin treatment; the treatment group was given letrozole combined with metformin. The therapeutic effects of the two groups were observed. Results The treatment effect of the treatment group was significantly higher than that of the control group, and the difference was significant (P 0.05). After treatment, the VAS score, serum CA125 of the two groups were significantly lower than those before treatment, and the differences were significant (P<0.05). The levels of VAS score, serum CA125 in the treatment group were significantly lower than the control group, and the differences were significant (P<0.05). Conclusions The effect of letrozole combined with metformin on patients with endometriosis is significant. It can effectively improve the curative effect, relieve dysmenorrhea symptoms, reduce the recurrence rate, and improve the quality of life of patients. It can be popularized and applied. Key words: Letrozole; Metformin; Endometriosis; Therapeutic effect
Full text 1,927 characters · extracted from oa-doi-fallback · click to expand
摘要目的：观察来曲唑联合二甲双胍治疗子宫内膜异位症的临床效果。方法选择2013年10月至2014年11月子宫内膜异位症患者112例，随机将其分为对照组和治疗组，每组56例。对照组采用亮丙瑞林治疗，治疗组采用来曲唑联合二甲双胍治疗。观察两组治疗效果。结果治疗组的治疗效果明显高于对照组，差异有统计学意义（P ﹤0.05）；治疗组复发率明显低于对照组，差异有统计学意义（P ﹤0.05）；治疗前，两组患者的 VAS 评分、血清 CA125相比，差异均未见统计学意义（P ﹥0.05）；治疗后，两组患者的 VAS 评分、血清 CA125均明显低于治疗前，差异均有统计学意义（P ﹤0.05）；治疗组患者的 VAS 评分、血清 CA125均明显低于对照组，差异均有统计学意义（P ﹤0.05）。结论对子宫内膜异位症的患者采用来曲唑联合二甲双胍治疗效果明显，能有效提高疗效，缓解痛经症状，降低复发率，改善患者生活质量，可于临床推广应用。 更多相关知识 abstractsObjective To observe the clinical effect of letrozole combined with metformin on en-dometriosis. Methods One hundred and twelve cases of endometriosis from October 2013 to November 2014 were randomly divided into control group and treatment group,with 56 cases in each group. The control group was given leuprorelin treatment;the treatment group was given letrozole combined with met-formin. The therapeutic effects of the two groups were observed. Results The treatment effect of the treatment group was significantly higher than that of the control group,and the difference was significant (P ﹤ 0. 05). The recurrence rate of the treatment group was lower than that of the control group,and the difference was significant( P ﹤ 0. 05). Before treatment,there was no significant difference in VAS score,serum CA125(P ﹥ 0. 05). After treatment,the VAS score,serum CA125 of the two groups were significantly lower than those before treatment,and the differences were significant(P ﹤ 0. 05). The lev-els of VAS score,serum CA125 in the treatment group were significantly lower than the control group,and the differences were significant(P ﹤ 0. 05). Conclusions The effect of letrozole combined with met-formin on patients with endometriosis is significant. It can effectively improve the curative effect,relieve dysmenorrhea symptoms,reduce the recurrence rate,and improve the quality of life of patients. It can be popularized and applied. More相关知识 - 浏览0 - 被引3 - 下载0 相似文献 - 中文期刊 - 外文期刊 - 学位论文 - 会议论文

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

endometriosisdysmenorrhea

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK